Drug – bio-affecting and body treating compositions – Extract – body fluid – or cellular material of undetermined... – Bile – bile acid – bile salt – amniotic fluid – or ascitic fluid
Reexamination Certificate
2000-01-07
2003-04-22
Witz, Jean C. (Department: 1651)
Drug, bio-affecting and body treating compositions
Extract, body fluid, or cellular material of undetermined...
Bile, bile acid, bile salt, amniotic fluid, or ascitic fluid
Reexamination Certificate
active
06551623
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to immunomodulating compositions, pharmaceutical agents containing the compositions, and the use of the compositions and agents in the treatment of animals.
BACKGROUND OF THE INVENTION
Therapies are continuously being developed for the prophylaxis and treatment of cancer and infectious diseases, such as Acquired Immunodeficiency Syndrome (AIDS). Some of these therapies attempt to use the immune system therapeutically. One approach is based on the antigen specific elements of the immune system, namely antibodies and T cells. For example, research has been aimed at developing vaccines against foreign agents, or against certain endogenous chemical messengers, such as interleukins, to suppress antibody reactions. A second approach is based on the isolation, cloning, expression and production of peptides and proteins from the non-antigen specific parts of the immune system. For example, proteins, such as cytokines, which comprise the interleukins produced by white blood cells, and interferons which stimulate lymphocytes and scavengers cells that digest foreign antigens, offer possibilities for therapies.
The treatment of cancer could be greatly enhanced if the early immune response to a tumor could be augmented so that the tumor does not reach a critical size. Strategies which have been suggested to augment the immune response to a tumor include vaccines specific for tumor-associated antigens; the use of monoclonal antibodies against antigens on the surface of tumor cells such as against the interleukin-2 receptor; the use of bispecific molecules containing antitumor antibodies and superantigens.
Relatively recently, the role of the physiologically active polypeptide, known as tumor necrosis factor (“TNF”) has been studied, particularly with respect to its ability to induce necrosis of tumors, with no effect upon the normal tissues of the living body. The amino acid sequence of TNF, as well as the base sequence of the DNA coding for TNF has been disclosed in U.S. Pat. No. 4,879,226.
Because TNF has been shown to have a role in inducing necrosis of tumors, any agent that can stimulate the production or bioavailability of TNF in vivo has potential utility as a treatment for various tumorous conditions. Additionally, any agent that can stimulate human monocytes and macrophages to produce TNF in vitro, is useful as a means for providing a source of TNF for therapeutic administration, as well as for analytical and diagnostic purposes.
Bile, which is secreted by the liver and stored in the gall bladder, has been investigated for various purposes, including the use of bile extracts to enhance bioavailability of drugs that are readily metabolized by normal liver function (see WO 90/12583) and to inhibit leucocytosis promotion in a mammal (see Shinoda et al.,
Chem. Pharm. Bull.,
30, 4429-4434 (1982)). However, bile has never been considered to be a source of therapeutically useful compositions with respect to neoplastic or infectious diseases. Interestingly, in accordance with British Patent No. 337,797, it was suggested to use the gall bladder itself as a potential source of anti-cancer agents, but only after the bile had been removed from the gall bladder, and the gall bladder thoroughly washed.
SUMMARY OF THE INVENTION
It has now been discovered that bile is an important source of a composition that can stimulate TNF production both in vitro and in vivo and is effective in treating various carcinomas, especially pancreatic cancer.
The bile composition of use is obtained by extraction of bile with a water soluble or miscible solvent. The extract so obtained may be further processed to remove unnecessary or undesirable components therefrom.
The product obtained by the process of extracting bile disclosed in further detail hereinbelow has been found to have TNF stimulating activity and is believed to have anti-cancer activity, especially against pancreatic and other cancers. Obviously, the entire composition so obtained may not be necessary to obtain such activity. Accordingly, it is possible to further separate, fractionate, or otherwise process the product thus obtained, and still retain the desired TNF stimulatory and anti-cancer activity. Moreover, it is envisioned that it is possible to obtain synthetically a product with the same or similar TNF stimulatory and anti-cancer activity. Thus, it is envisioned that the components of the product may be analyzed as to the components, or combination thereof, that are responsible for the desired activity, and a synthetic product made, based on such analysis.
In one aspect, the present invention relates to a composition for use as an immunomodulator comprising small molecular weight components of less than 3000 daltons, and having one or more of the following properties:
a) is extractable from bile of animals;
b) is capable of stimulating monocytes and macrophages in vitro;
c) is capable of modulating tumor necrosis factor production;
d) contains no measurable level of IL-1&agr;, IL-1&bgr;, TNF, IL-6, IL-8, IL-4, GN-CSF or IFN-gamma;
e) has an anti-proliferative effect in a malignant mouse hybridoma cell line;
f) shows no cytotoxicity to human peripheral blood mononuclear cells; and
g) is not an endotoxin.
In accordance with a preferred embodiment the composition is extracted from the bile of bovines and is capable of stimulating the release of tumor necrosis factor.
The composition of the invention may be prepared by (a) mixing bile from an animal, preferably a bovine, with a solvent that is soluble or miscible with water, preferably an alcohol, and preferably with an equal volume of an alcohol, to produce a bile/alcohol solution; (b) separating the solution which preferably is an alcohol soluble fraction, and isolating therefrom a solution substantially free of alcohol, as by removing most of the alcohol, such as by the use of heat; (c) removing bile pigments from the solution to obtain a colorless liquid; (d) optionally treating the colorless liquid to substantially remove any residual alcohol; (e) removing fatty organic materials, as by extracting the colorless liquid with ether and isolating the aqueous phase; and (f) optionally removing residual ether from the aqueous phase.
The composition may be used without further modification by simply packaging it in vials and sterilizing. The composition may be also be used in a concentrated form. A preferred concentrated form is prepared as follows. Prior to step (e) the colorless liquid may optionally be concentrated to about one eighth of the volume of the bile/alcohol solution and after step (f) the aqueous phase may be concentrated so that it is one tenth of the volume of the bile/ethanol solution.
The invention also relates to a pharmaceutical agent comprising the novel composition of the invention.
The invention further relates to a method of treating a patient comprising administering to said patient an effective amount of a composition of the invention. The invention still further relates to the use of a composition of the invention in the prophylaxis and treatment of diseases and conditions requiring modulation of the immune response; preferably infectious diseases and neoplasias.
REFERENCES:
patent: 4372949 (1983-02-01), Kodama et al.
patent: 4562179 (1985-12-01), Teraji et al.
patent: 4585762 (1986-04-01), Teraji et al.
patent: 4767610 (1988-08-01), Long
patent: 4837023 (1989-06-01), Eibl
patent: 4879226 (1989-11-01), Wallace et al.
patent: 4900724 (1990-02-01), Kato et al.
patent: 4916249 (1990-04-01), Brachwitz et al.
patent: 4935520 (1990-06-01), Nojima et al.
patent: 4965391 (1990-10-01), Counsell et al.
patent: 5049552 (1991-09-01), Eibl
patent: 5081245 (1992-01-01), Nomura et al.
patent: 5087721 (1992-02-01), Counsell et al.
patent: 5103007 (1992-04-01), Nomura et al.
patent: 5118674 (1992-06-01), Braquet et al.
patent: 5138067 (1992-08-01), Kamata et al.
patent: 5310958 (1994-05-01), Mizushima
patent: 5369097 (1994-11-01), Salari et al.
patent: 0285285 (1988-10-01), None
patent: 337797 (1930-12-01), None
patent: WO 89/06977
Goldberg Joshua B.
Juneau Todd L.
Lorus Therapeutics Inc.
Nath Gary M.
Witz Jean C.
LandOfFree
Immunomodulating compositions from bile does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunomodulating compositions from bile, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunomodulating compositions from bile will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3012550